KBI Biopharma, Inc. Expands Global Portfolio with Launch of SUREmAb™ for Faster Monoclonal Antibody Development and Manufacturing
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced the launch of SUREmAb™, an offering built on the robustness of KBI’s SUREtechnology Platform™, that allows for optimized, safe, and cost-efficient monoclonal antibody (mAb) development and manufacturing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230912612750/en/
(Photo: Business Wire)
SUREmAb is a vertically integrated global offering designed to minimize development timelines for global biopharmaceutical manufacturers, delivering research cell bank (RCB) development in as little as 9 weeks and the ability for customers to move from DNA to GMP drug substance in as few as 11 months. In addition, SUREmAb is engineered to achieve titers of up to 10 g/L with a lower-cost workflow to optimize operational efficiency and maximize ROI.
"SUREmAb represents not just the culmination of decades of biologics production expertise but our vision for the future of mAb development,” said KBI Chief Scientific Officer, Sigma Mostafa. “In an era where time, efficiency, and innovation converge, we're proud to introduce a platform that can not only accelerate the development journey but is high quality and cost-effective, from the start. At KBI, we believe in anticipating market shifts and pioneering solutions that address tomorrow's challenges today, and SUREmAb is a testament to that commitment."
The operational consolidation of KBI Biopharma and Selexis, announced during BIO International 2023, played an important role in the operations that power the SUREmAb technology, enabling KBI to streamline processes and offer greater efficiencies in monoclonal antibody development and manufacturing. This offering strengthens KBI’s industry expertise and position within global markets by building on more than 15 years of mAb development leadership, with over 150 unique therapeutic mAb projects and 7 commercialized mAbs leveraging the SUREtechnology Platform.
“We recognize the need to be a strong partner for customers with novel therapies so that they have the best chance of reaching as many patients as possible,” said KBI CEO, J.D. Mowery. “The simplified access to SUREmAb and ongoing manufacturing with KBI shows our commitment to supporting the industry by improving a key barrier to development.”
SUREmAb complies with global regulatory standards, ensuring straightforward experiences when targeting markets regulated by the US FDA, EMA and PMDA.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 400 drug candidates in preclinical and clinical development and the manufacture of 10 commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230912612750/en/
Contact information
KBI Biopharma, Inc. Company Inquiries
Sarah Wakefield
KBI Biopharma, Inc.
swakefield@kbibiopharma.com
KBI Biopharma, Inc. Media Inquiries
Blair Ciecko
CG Life
bciecko@cglife.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Digital Technologies Hosts Trust Bridge Forum at Hong Kong Fintech Week 2024 and Unveils "Dual Chains and One Bridge" Solution6.11.2024 05:48:00 EET | Press release
Ant Digital Technologies hosted the Trust Bridge Forum at Hong Kong Fintech Week, bringing together key industry leaders and experts to discuss the opportunities and challenges presented by real-world asset (RWA) tokenization. Mr. George Chou, Chief Fintech Officer of the Hong Kong Monetary Authority (HKMA), delivered the opening remarks, highlighting HKMA's commitment to driving fintech innovation, particularly through initiatives like Project Ensemble.“The HKMA recognise that CBDCs have the potential to unlock unrealised economic value by transforming the ways we transact and the systems we transact on,” stated Mr. Chou. “Collaboration between the public and private sectors is crucial to success. We look forward to continuing collaboration with the world and all relevant industry participants.” Dr. Ying Yan, Chief Scientist at Ant Digital Technologies, provided insights into the evolution of Web3 technology and AntChain’s trusted digital-twin technology which is centered around block
IFF Reports Third Quarter 2024 Results5.11.2024 23:37:00 EET | Press release
IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2024. Management Commentary “We are pleased to report a strong performance in the third quarter, with growth across all business segments,” stated IFF CEO Erik Fyrwald. “Market recovery off prior year lows and our global team's passion to address the needs of our customers drove notable volume recovery in every division. This achievement, coupled with our focus on productivity, has resulted in significant bottom-line improvement compared to the same period last year. Taking into account our strong performance in the third quarter and our continued cautiously optimistic outlook for the fourth quarter, we are increasing our full year 2024 financial guidance. We are making solid progress but have a lot of exciting work ahead of us to unleash the full potential of IFF.” Third Quarter 2024 Consolidated Financial Results Reported net sales for the third quarter were $2.93 billion, an increase of 4% versus th
Burjeel Holdings and Response Plus Medical launch $1mn Human Energy Health and Wellbeing Award5.11.2024 20:17:00 EET | Press release
Burjeel Holdings, a leading super-specialty healthcare provider in the MENA region, and Response Plus Medical Services (RPM), the largest pre-hospital care and emergency medical services provider in the region, have jointly launched the $1 million Human Energy Health and Wellbeing Award at ADIPEC 2024 to boost workplace wellness across the global Energy sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241105689488/en/ Burjeel Holdings and Response Plus Medical launch $1mn Human Energy Health and Wellbeing Award (Photo: AETOSWire) The global energy sector has made significant strides in prioritising the health and wellbeing of its workforce. Building on this, Dr. Shamsheer Vayalil, Founder & Chairman – Burjeel Holdings, and Omran Al Khoori, Chairman – RPM Holding, announced the award during ADIPEC 2024, encouraging CEOs from major global energy organisations to further advance wellbeing across the industry. The award fo
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 20245.11.2024 16:05:00 EET | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share new data across a range of B-cell malignancies and assets, including best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib), at the 66th ASH Annual Meeting and Exposition in San Diego, December 7-10. BeiGene has 21 abstracts accepted at ASH 2024, with four selected for oral presentation. “In the five years since its initial approval, BRUKINSA has become a standard of care for patients facing many B-cell malignancies, and our data featured at ASH demonstrated how long-term follow-up of treatment with BRUKINSA elicited deep and durable responses, including in patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia,” said Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “BRUKINSA is just the starting point – pipeline data for our BTK degrader BGB-16673 and BCL2 inhibitor sonrotoclax showcase our contin
DirectSens’ Market-Leading LactoSens ® Biosensor Technology Acquired by Kerry Group P.L.C.5.11.2024 15:00:00 EET | Press release
DirectSens, a pioneer in next generation biosensor technology, announces the acquisition of its LactoSens® technology by Kerry Group, a global leader in taste and nutrition. The acquisition of LactoSens® reflects DirectSens’ success in developing end-to-end biosensor solutions and represents a move by Kerry Group to complement its offering in lactase enzymes. As an indispensable analytical tool, LactoSens® will work alongside Kerry Group’s ingredient solutions, enabling a more integrated offering for food manufacturers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241105399369/en/ LactoSens®, Industry Gold Standard Biosensor Kit. Developed and manufactured by DirectSens in Vienna, AUSTRIA, © DirectSens GmbH 2024 “We’re excited to bring LactoSens® into Kerry Group’s portfolio to add a new element to our offering, as we fully integrate LactoSens® into our broader solutions for the food and beverage industry.” — Ronan Moloney
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom